Sling Raises $123 Million for Phase III Linsitinib

Company Sling Therapeutics Event Type Financing (Series C) Platform Oral Small-Molecule IGF-1R Inhibitor Indication Active Moderate-to-Severe Thyroid Eye Disease Summary Sling Therapeutics closed a $123 million Series C led by Forbion, with participation from existing investor TPG Life Sciences Innovations and new investor Sectoral Asset…